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eveloping resistance to drugs against MRSA
. Gould
Aberdeen Royal Inﬁrmary, Aberdeen, Saudi Arabia
Across the world, vancomycin has shown a surprising resilience
o being displaced as the ﬁrst choice treatment for serious MRSA
nfection. With the ﬁrst description of low level resistance (VISA
nd hVISA in the late 1990s) an urgency to develop new MRSA
rugs developed, further stimulated by the emergence of high level
ancomycin resistance in the early 2000s. High level resistance
asn’t become a clinical problem yet and VISA has, arguably, not
merged as a signiﬁcant problem either. What is much more sig-
iﬁcant numerically, and probably even clinically are hVISA and
o-called MIC creep or leap, with vancomycin MICs elevated above
ild-type values but still within internationally accepted break-
oints (BPs). A growingbodyof published studies now identify such
trains as the norm and also that clinical response in serious infec-
ion is impaired. It has to be accepted, however, that this is a very
ontroversial area.MIC testing systems are at their limit of sensitiv-
ty and there is little clinical evidence that increasing vancomycin
ose to improve PK/PD target attainment has any beneﬁcial effect.
ancomycin is however, perceived by many to be at the end of
ts useful life for treating serious infections. Its therapeutic ratio is
ow just too narrow. Recent IDSA guidelines fail to acknowledge
his situation, however.
Newdrugs such as linezolid and daptomycin aremaking signiﬁ-
ant inroads into clinical use but both are troubled by early reports
f resistance, some of it plasmid mediated. Old drugs too are also
eing used increasingly, but resistance is an emerging issue here
oo.
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mplications
. Apisarnthanarak
Thammasat University Hospital, Pratumthani, Thailand
In most parts of the world, methicillin-resistant Staphylococ-
us aureus (MRSA) infection have continued to increase despite
ntensive infection-control efforts. Some groups have advocated
searchanddestroy”policies that recommend routine screening for
RSA to identify, isolate, and treat carriers, with the ultimate goal
f eradicating the pathogen from health care facilities. All MRSA
arriers are not the same; carriage may be transient, intermit-
ent, or persistent for months to years. Persistent carriers are morenfectious Diseases 16S (2012) e2–e157
heavily colonized (frequently at multiple sites), are more likely to
transmit to others, and are more likely to become infected than
transient carriers. Methods to eradicate MRSA have included the
use of oral antibiotics plus rifampin. The use of rifampin ensures
excellent penetration into secretions and tissues. The use of com-
bination therapy has been effective in treating MRSA in the nares
and at other sites. However, the wide-scale use of systemic antibi-
otics has been associated with the development of drug resistance
and the loss of valuable therapeutic agents for subsequent treat-
ment of infection. As a result of this drug-resistance issue, topical
antibacterial agents and germicides have been the preferred inter-
vention for MRSA eradication programs. Therefore, chlorhexidine
and/or mupirocin to decolonize patients. Increased mupirocin use
has been associated with increased drug resistance and failure to
clear the organism. The gene for high-level mupirocin resistance,
mupA, suggesting that the future usefulness of this drug might lim-
ited. Increased resistance ofMRSA to systemic antibiotics following
decolonization regimens has also been an issue in this study and
others. Resistance to other germicides in MRSA has been reported
following wide-scale use; whether resistance to chlorhexidine and
its clinical implications will become an issue is not yet known. In
this presentation, I will discuss decolonization strategy, resistant
to agents for MRSA decolonization and its clinical implications.
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PK/PD considerations when treating MRSA
T. Mazzei
University of Florence, Florence, Italy
Treatment of MRSA infections may often represent a life-
threatening challenge and clinicians should be conﬁdent and apply
the most advanced pharmacokinetic/pharmacodynamic (PK/PD)
knowledge. There are in fact extensive data showing that the
administration of antimicrobials according to PK/PD parameters
improves the possibility of a positive clinical outcome, particularly
in severely ill patients.
The three main PK/PD parameters able to predict antimicrobial
efﬁcacy are the maximum concentration (Cmax)/minimum
inhibitory concentration (MIC) ratio, the area under the
concentration-time curve (AUC/MIC) ratio and the time dur-
ing which the drug concentration exceeds the MIC (T>MIC). The
relative importance of the three PK/PDparameters varies according
to different antimicrobial classes, and sometimes overlaps.
Moreover, critically ill patients require great attention in terms
ofdosages, posologyandadministration routeof antimicrobialsdue
to the many pathophysiological changes occurring during a severe
acute illness or sepsis (i.e. increased capillary permeability, third
spacing, increase of volume of distribution, variation of renal or
liver function). All these factors may affect a drug’s pharmacoki-
netics, especially the hydrophilic, renally excreted antibacterials
(e.g. b-lactams, aminoglycosides and glycopeptides). Therefore, the
serum and tissue concentrations achieved when these drugs are
administered at dosages suggested for healthy volunteers are often
suboptimal. The pharmacological strategies to be used in these
patients are, for example, to increase doses and/or time of infusion
